

Gerresheimer – A Leading Partner for the Pharma and Healthcare Industry

**Commerzbank
German Investment Seminar**

New York

January 10+11, 2011

Uwe Röhrhoff, CEO

Disclaimer

- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Gerresheimer – Who we are and what we do

- Gerresheimer is an important partner of the pharmaceutical and healthcare industry.
- Innovations in the application of pharmaceutical products are innovations that people benefit from and which improve their quality of life.
- Our products make a practical and significant contribution to health and well-being.

Gerresheimer at a glance

Consolidated net revenues LTM August 2010: EUR 1,009.0m

EUR 312.2m; 31%



Tubular Glass

adj. EBITDA margin:
24.5%

EUR 298.0m; 29%



Plastic Systems

adj. EBITDA margin:
24.3%

EUR 321.9m; 31%



Moulded Glass

adj. EBITDA margin:
20.6%

91.1m; 9%




**Life Science
Research**

adj. EBITDA
margin:
10.6%

Gerresheimer is a global player

Region	Locations	Employees
Europe	19	5,252
Americas	14	2,860
Asia	7	1,433
Total	40	9,545



As of August 31, 2010

Leading market positions in attractive niche markets

Division	Tubular Glass (Injectable Glass and Systems)			Plastic Systems (Plastic Drug Delivery and Systems)				Moulded Glass	Life Science Research
	Tubing	Syringes	Other Injectables	Plastic Packaging	Inhalation (DPI) ¹	Diabetes Diagnostics ²	Pens	OTC Liquids and Syrups Bottles	Glass Consumables & Equipment
North America	# 1	# 2	# 1		started			# 1	# 1
Europe	# 2	# 2	# 2	# 1	# 1	# 2	started	# 2	
China		# 2	# 1						# 1

Source: Company Information

¹ DPI = Dry Powder Inhaler

² Includes lancets and lancing devices only

Well-diversified blue-chip customer base

Pharma and healthcare




Other



Gerresheimer has close long-term relationships with leading global accounts...

Net revenues to TOP 50 customers (FY 2009) in EUR m



...with limited dependence on individual customers.

Gerresheimer provides its pharma and healthcare customers with solutions across all key product categories

Division	Tubular Glass (Injectable Glass and Systems)			Plastic Systems (Plastic Drug Delivery and Systems)				Moulded Glass		Life Science Research
	Glass Tubing	Syringes	Other Injectables	Inhalers	Plastic Packaging	Diabetes Diagnostics ²	Pens	Pharma (Type I)	OTC liquids and Syrups (Type II & III)	Glass Consumables & Equipment
Gerresheimer	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Schott	✓	✓	✓							
Becton Dickinson ¹		✓				✓				
Ancor Alcan ¹	✓		✓		✓					
Ompi			✓							
Nypro				✓	✓	✓	✓			
Consort Medical ¹				✓						
West Pharma ¹				✓			✓			
Rexam ¹				✓	✓		✓			
Facet						✓				
Ypsomed ¹							✓			
Desjonquères								✓	✓	
Rocco Bormioli								✓	✓	
Duran										✓
Corning ¹										✓

¹ Public company

² Includes lancets and lancing devices only

Source: Company estimates

Selected growth opportunities

**Pharmerging
Markets**


Generics

RTF® syringes

Diabetes

Acquisitions

Our strategy is built to deliver



Q1-Q3 2010 Revenues, adjusted EBITDA and adjusted EPS

Revenues	Q1-Q3 '10 EUR m	▲ vs. Q1-Q3 '09 EUR m	Reported Growth in %	Growth at Const. FX Rate in %
Total Group ²	753.0	+38.1	+5.3	+4.4

Adjusted EBITDA ¹	Q1-Q3 '10 EUR m	▲ vs. Q1-Q3 '09 Growth in %	Q1-Q3 '10 Margin in %	Q1-Q3 '09 Margin in %
Total Group ²	147.9	+15.5	19.6	17.9

Earnings	Q1-Q3 '10 EUR	Q1-Q3 '09 EUR
Adjusted EPS	1.33	0.83

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

² Excl. TPS, sold as of July 1, 2009

2010 Key financial figures

	August 31, 2010 EUR m	August 31, 2009 EUR m	▲ in %
Equity	509.3	466.5	+9.2
<i>Equity ratio in %</i>	37.7	34.7	
Net Working Capital ¹	179.3	180.8	-0.8
<i>in % of LTM revenues</i>	17.8	17.7	
Net Financial Debt ²	356.6	430.7	-17.2
Adjusted EBITDA leverage	1.7	2.3	n/a
	Q1-Q3 2010 EUR m	Q1-Q3 2009 EUR m	▲ in %
Capital expenditure	43.0	50.3	-14.5
Free cash flow	47.3	-19.8	>100%

¹ Inventories (incl. prepayments) and trade receivables less trade payables and payments received on account of orders

² Total amount of debt less cash and cash equivalents

Confirmation of FY 2010 Guidance

	2009 ¹	Guidance 2010 (as of Feb 10, 2010)	Confirmed Guidance 2010 (as of July 14, 2010)
Net Revenues	EUR 970.8m	+2% to 4% as reported ² +2% to 4% at const. FX	+5% to 6% as reported ³ +3% to 4% at const. FX
Adj. EBITDA margin	19.2%	Mid 19%	19.5% to 20.0%
Capex	EUR 86.4m	EUR 75m to 80m	EUR 75m to 80m

¹ Excluding TPS

² Exchange rate assumption for FY 2010: EUR 1.00 = USD 1.40 (FY 2009 average exchange rate: EUR 1.00 = USD 1.38)

³ Exchange rate assumption for FY 2010: EUR 1.00 = USD 1.30 (FY 2009 average exchange rate: EUR 1.00 = USD 1.38)

- Appendix

Q3 2010 P&L overview

	Q3 2010 EUR m	Q3 2009 EUR m	▲ in %
Total revenues ex TPS	259.4	236.9	+9.5
Adjusted EBITDA ¹	53.3	42.0	+26.9
EBITA	32.1	22.4	+43.3
Amortization of FV adjustments	5.8	9.5	-39.0
Profit before interest and taxes (EBIT)	26.3	12.9	>100
Financial result	-8.9	-9.9	-10.1
Profit before taxes	17.4	3.0	>100
Net income	14.1	-4.0	>100
EPS	0.41	-0.11	>100
Adjusted EPS ²	0.52	0.20	>100

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

² Adjusted net income after minorities divided by 31.4m shares

Q3 2010 Revenues by division

	EUR m	Reported growth [%]	FXN ¹ [%]
Total revenues	259.4	+6.9	+3.4
Total revenues ex TPS	259.4	+9.5	+5.8
Tubular Glass	77.3	+4.3	-0.7
Plastic Systems	75.3	+0.7	-0.9
Plastic Systems ex TPS	75.3	+9.0	+7.1
Moulded Glass	85.2	+13.9	+11.5
Life Science Research	25.8	+18.3	+8.0

¹ FXN = Growth at constant exchange rate

Q3 2010 Adjusted EBITDA¹ & margin by division

	Q3 2010 EUR m	▲ vs. Q3 2009 [Growth in %]	Q3 2010 [Margin in %]	Q3 2009 [Margin in %]
Total Group	53.3	+26.9	20.5	17.3
Total Group ex TPS	53.3	+28.1	20.5	17.6
Tubular Glass	18.3	+4.0	23.7	23.8
Plastic Systems	17.5	+6.1	23.2	22.1
Plastic Systems ex TPS	17.5	+8.7	23.2	23.3
Moulded Glass	19.6	+78.2	23.0	14.7
Life Science Research	3.2	+60.0	12.4	9.2

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

Q3 2010 Key financial figures

	August 31, 2010 EUR m	August 31, 2009 EUR m	▲ in %
Equity	509.3	466.5	+9.2
<i>Equity ratio in %</i>	37.7	34.7	
Net Working Capital ¹	179.3	180.8	-0.8
<i>in % of LTM revenues</i>	17.8	17.7	
Net Financial Debt ²	356.6	430.7	-17.2
Adjusted EBITDA leverage	1.7	2.3	n/a
	Q3 2010 EUR m	Q3 2009 EUR m	▲ in %
Capital expenditure	13.5	19.1	-29.3
Free cash flow	48.3	15.1	>100%

¹ Inventories (incl. prepayments) and trade receivables less trade payables and payments received on account of orders

² Total amount of debt less cash and cash equivalents

Financing structure

Comparison of debt/cash positions in EUR m

Net Financial Debt

Q3 2009: 430.7m

Bond

126.0

Long-term bank debt

209.6

Revolving bank debt

75.1

Local borrowings

47.3

Leasing

17.6

Cash

44.9

Q3 2010: 356.6m

126.0

188.3

40.0

41.5

13.3

52.5

Interest rate (due date):

7.9%; Fixed coupon (2015)

Hedged interest rate: 5.7% until Sep 2010. As from Sep 2010 ca. 95% hedged at 1.8% until Sep 2012 (2012/2013)

55bps over Euribor/Libor, Headroom: EUR 135.0m (2012/2013)

As of August 31, 2009 + 2010

Q1-Q3 2010 P&L overview

	Q1-Q3 2010 EUR m	Q1-Q3 2009 EUR m	▲ in %
Total revenues ex TPS	753.0	714.9	+5.3
Adjusted EBITDA ¹	147.9	127.8	+15.7
EBITA	82.0	62.5	+31.2
Amortization of FV adjustments	18.6	28.6	-35.0
Profit before interest and taxes (EBIT)	63.4	33.9	+87.0
Financial result	-26.9	-30.6	-12.1
Profit before taxes	36.5	3.3	>100
Net income	27.7	-4.1	>100
EPS	0.85	-0.15	>100
Adjusted EPS ²	1.33	0.83	+60.2

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

² Adjusted net income after minorities divided by 31.4m shares

Q1-Q3 2010 Revenues by division

	EUR m	Reported growth [%]	FXN ¹ [%]
Total revenues	753.0	+1.2	+0.2
Total revenues ex TPS	753.0	+5.3	+4.4
Tubular Glass	234.3	+4.1	+3.0
Plastic Systems	221.6	-7.1	-8.4
Plastic Systems ex TPS	221.6	+6.0	+4.4
Moulded Glass	238.9	+6.2	+6.0
Life Science Research	69.8	+5.8	+4.5

¹ FXN = Growth at constant exchange rate

Q1-Q3 2010 Adjusted EBITDA¹ & margin by division

	Q1-Q3 2010 EUR m	▲ vs. Q1-Q3 '09 [Growth in %]	Q1-Q3 2010 [Margin in %]	Q1-Q3 2009 [Margin in %]
Total Group	147.9	+15.7	19.6	17.2
Total Group ex TPS	147.9	+15.5	19.6	17.9
Tubular Glass	56.3	+5.8	24.0	23.6
Plastic Systems	51.3	+8.0	23.1	19.9
Plastic Systems ex TPS	51.3	+7.3	23.1	22.9
Moulded Glass	47.8	+35.0	20.0	15.7
Life Science Research	7.6	+24.6	10.9	9.2

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

Financial calendar

- **February 10, 2011** Annual Report 2010
- **April 7, 2011** Interim Report 1st Quarter 2011
- **April 14, 2011** Annual General Meeting
- **July 13, 2011** Interim Report 2nd Quarter 2011
- **October 6, 2011** Interim Report 3rd Quarter 2011

Investor Relations contact details

■ **Phone** +49 211 6181-257

■ **Fax** +49 211 6181-121

■ **E-mail** gerresheimer.ir@gerresheimer.com

■ **IR website** www.gerresheimer.com/ir